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gained.
Cost data:
The direct health costs included medications and premedications, monitoring, adverse events, subsequent treatment, disease-related morbidity, and palliative care. The cost data were from Medicare reimbursement rates and PharMetrics claims databases. All costs were in US dollars ($).
Analysis of uncertainty:
: One-way sensitivity analyses were performed, focusing mainly on the cost inputs and the comparison between cisplatin plus pemetrexed and cisplatin plus gemcitabine. The results were presented in tornado diagrams.
Results
In patients with advanced non-squamous non-small cell lung cancer, the analysis suggested that two-year treatment with carboplatin plus paclitaxel cost $52,885 and yielded 0.8945 life-years and 0.4513 QALYs; cisplatin plus gemcitabine cost $61,008 and yielded 0.9112 life-years and 0.4676 QALYs; cisplatin plus pemetrexed cost $65,517 and yielded 0.9652 life-years and 0.5016 QALYs; and carboplatin, paclitaxel and bevacizumab cost $90,044 and yielded 1.0379 lifeyears and 0.5260 QALYs.
The cost-utility ratio for cisplatin plus pemetrexed compared with cisplatin plus gemcitabine was $132,829 per QALY gained; for cisplatin plus pemetrexed compared with carboplatin plus paclitaxel the ratio was $250,992 per QALY gained; and the ratio for carboplatin, paclitaxel and bevacizumab compared with cisplatin plus pemetrexed was $1,006,065.
For all patients with NSCLC, carboplatin, paclitaxel and bevacizumab was not considered. The cost-utility ratio for cisplatin plus pemetrexed compared with cisplatin plus gemcitabine was $175,597 per QALY gained; and for cisplatin plus pemetrexed compared with carboplatin plus paclitaxel it was $343,870 per QALY gained.
The results of the univariate sensitivity analyses suggested that reasonable changes in the costs changed the cost-utility ratio for cisplatin plus pemetrexed compared with cisplatin plus gemcitabine by less than 10%.
